
Opinion|Videos|October 25, 2024
Therapies Beyond the Front Line for SCLC
Key Takeaways
- Tarlatamab is a newly approved therapy, marking progress beyond first-line treatments for SCLC.
- Researchers are exploring novel agents and combination therapies to enhance patient outcomes in SCLC.
Panelists discuss how treatment options for small cell lung cancer (SCLC) extend beyond first-line therapies and the recently approved tarlatamab, exploring existing treatments in the second-line and beyond while also highlighting promising ongoing clinical trials and emerging therapies that show potential for improving outcomes in SCLC patients.
Advertisement
Episodes in this series

We’ve discussed first-line therapies and a newly approved therapy tarlatamab.
- Beyond first-line therapies, what options exist for patients, and what clinical trials are you excited about?
- What are some of the therapies being researched for small cell lung cancer (SCLC) that you are excited about?
How do you see the management of SCLC evolving in the future?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5